SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Merck Initiates Its ENHANCE-3 Phase 3 Randomized Clinical Trial Evaluating OHTUVAYRE For The Prevention Of Chronic Obstructive Pulmonary Disease
FDA Issues Emergency Use Authorization For Drug To Treat New World Screwworm Infestations In Dogs, Puppies
**Tomorrow, October 27, 2026, the U.S. FDA approved Zyda Life Sciences’ ANDA-based generic entry for [Insert Generic Name Here], a move that analysts anticipate will introduce imme…
Alembic Pharmaceuticals has received FDA approval for drug ANDA217267, though specific details regarding the approval's subject are pending further disclosure. This development ind…
Approval and launch of a short-acting insulglargine biologic for Type 1 diabetes on October 23, 2026, expand BIONPHARMA’s insulin portfolio with a differentiated formulation poised…
Sandoz Inc. announced the submission of a Biologics License Application (BLA) by the FDA on October 22, 2026, marking a pivotal step toward commercialization whose primary market i…
NOVITIUM PHARMA announced the approval of its generic application, ANDA220010, on October 15, 2026. This regulatory clearance is expected to drive significant revenue growth and in…
COSETTE Pharmaceuticals has announced the authorization of a new NDA, marking its latest portfolio expansion following the 2026 product launch. Financial analysts anticipate this s…
Amneal Pharmaceuticals announced Friday that its ANDA-approved product is now available on the U.S. market, marking a new competitive entry for the corresponding branded therapy. T…
Humanwell Puracap announced today that the FDA approved its ANDA221049, paving the way for the launch of a generic alternative as the market moves into 2026. This regulatory approv…
**STRIDES PHARMA INTL** announced that on October 13, 2026, the FDA approved its Abbreviated New Drug Application (ANDA #208359), which is expected to allow for the late-entry mark…
The FDA has approved a new treatment from Aicuris Anti-Infective Cures AG aimed at addressing identified health needs effective October 9, 2026, potentially transforming market dyn…
Lupin announced the receipt of final FDA approval for a Abbreviated New Drug Application, signaling a potential entry into a valued therapeutic market. This regulatory clearance is…
Taro Pharmaceutical Industries announced FDA approval of the pending ANDA220722, signaling the final regulatory step in securing market entry; this clearance sets the stage for Tar…
FDA has granted approval to Zydus Lifesciences under ANDA 218361, paving the way for the manufacturer to potentially enter a new market segment and challenge competitors with the l…
Uppersmith Labs announced the FDA approval of its ANDA for the generic drug on September 28, 2026, setting the stage for imminent market entry. This filing is expected to drive dil…
NEPHRON has obtained FDA approval for its Abbreviated New Drug Application (ANDA216254), paving the way for a generic entry that is expected to significantly undermine the market d…
Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component
Johnson & Johnson Announces That TREMFYA Met Primary And Major Secondary Endpoints Demonstrating Both Improvement In Axial Symptoms And Reduction In Inflammation By MRI Assessment …
Despite the preliminary designation, YICHANG HUMANWELL’s anticipated FDA approval for the generic version of this unspecified therapeutic, targeted for September 25, 2026, is expec…